

195. A method of directly activating B cells using a soluble polypeptide having the amino acid sequence selected from the group consisting of leu-leu-leu-leu-leu-leu-pro-ser; leu-leu-leu-leu-leu-leu-pro-leu; and leu-leu-leu-leu-leu-leu-val-his, and which is specifically recognized by the monoclonal antibody 3C10 and which activates B cells, by administering to a mammal in need thereof an effective amount of said polypeptide.

## REMARKS

Claims 159 to 195 are pending in the application.

No new matter has been added by amendments made herein, the nature of which is more fully described below.

The description (specification) has been amended to correct obvious clerical errors.

The claims have been amended to reduce their number from that contained in the international application from which this application claims priority.

The Sequence Listing has been amended to meet PTO requirements by insertion, into the general information section of the listing, of the serial number and filing date of this application, etc. The sequences have not been amended and are the same as those submitted in connection with international patent application No. PCT/CA 99/00482, from which this application claims priority.

No new matter has been added by the amendments to the Sequence Listing.

The content of the enclosed paper and accompanying computer readable copies of the Sequence Listing are the same.

Should any Patent Office Official want to telephone, the call should be made to John C. Hunt (Registration No. 36,424) at (416) 863-4344.

Yours very truly,



John C. Hunt  
Registration No. 36,424

July 31, 2001  
Date

**BLAKE, CASSELS & GRAYDON LLP**  
Box 25, Commerce Court West  
Toronto, Ontario  
M5L 1A9  
Canada

- Enclosures:
1. Substitute specification (pages 1 to 32).
  2. Substitute claims (pages 1 to 5).
  3. Specification, "Version with Markings to Show Changes Made" (pages 1 to 12).
  4. Paper copy of Sequence Listing (pages 1/9 to 9/9).
  5. Sequence Listing Diskette.